Edition:
United Kingdom

Zhejiang Huahai Pharmaceutical Co Ltd (600521.SS)

600521.SS on Shanghai Stock Exchange

29.25CNY
3:09am GMT
Change (% chg)

¥0.05 (+0.17%)
Prev Close
¥29.20
Open
¥29.00
Day's High
¥29.67
Day's Low
¥28.75
Volume
6,730,975
Avg. Vol
5,628,966
52-wk High
¥30.38
52-wk Low
¥18.09

Latest Key Developments (Source: Significant Developments)

Zhejiang Huahai Pharmaceutical passes U.S. FDA approval
Friday, 13 Oct 2017 

Oct 13(Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>:Says it received approval for a kind of tablet, which is used for treatment of chronic hepatitis B, from U.S. Food and Drug Administration .Says it will be able to sell the tablet in the United States after receiving the FDA approval.  Full Article

Zhejiang Huahai Pharmaceutical's H1 net profit up 14.1 pct y/y
Sunday, 20 Aug 2017 

Aug 20 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>:Says its H1 net profit up 14.1 percent y/y at 295.4 million yuan ($44.29 million).  Full Article

Zhejiang Huahai Pharmaceutical gets FDA approval
Thursday, 25 May 2017 

May 25(Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS> ::* Says it received FDA approval for duloxetine capsules from U.S Food and Drug Administration.  Full Article

Zhejiang Huahai Pharmaceutical to set up medical health investment management JV
Friday, 14 Oct 2016 

Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>: Says it to set up a medical health investment management JV with a Shanghai-based fund management firm .Says the co to hold 50 percent stake in the JV.  Full Article

Zhejiang Huahai Pharmaceutical passes FDA approval
Tuesday, 16 Aug 2016 

Zhejiang Huahai Pharmaceutical Co., Ltd. <600521.SS>: Says it receives approval for its voriconazole tablets from U.S Food and Drug Administration .Says company will be able to sell its voriconazole tablets in the United States after receiving the FDA approval.  Full Article

Zhejiang Huahai Pharmaceutical to transfer stake in Vivo Panda Fund to unit
Thursday, 4 Aug 2016 

Zhejiang Huahai Pharmaceutical Co., Ltd. <600521.SS>:Says it plans to transfer 9.97 percent stake in Vivo Panda Fund to its HK-based wholly-owned unit, for $ 10 million.  Full Article

Zhejiang Huahai Pharmaceutical adjusts private placement plan
Tuesday, 7 Jun 2016 

Zhejiang Huahai Pharmaceutical Co., Ltd. <600521.SS> : Says it amends the private placement plan due to dividend payment .Says new plan is to issue up to 19.6 million new shares at 15.44 yuan per share, for 302.6 million yuan in total.  Full Article

ZHEJIANG HUAHAI PHARMACEUTICAL says 2015 dividend payment date
Tuesday, 31 May 2016 

ZHEJIANG HUAHAI PHARMACEUTICAL <600521.SS> CO.,LTD: Says it will pay a cash dividend of 2 yuan (before tax) per 10 shares and use additional paid-in capital to distribute 3 new share for every 10 shares, to shareholders of record on June 3 for 2015 .Says the company's shares will be traded ex-right and ex-dividend on June 6 and the dividend will be paid on June 6.  Full Article

Zhejiang Huahai Pharmaceutical passes FDA approval
Friday, 20 May 2016 

Zhejiang Huahai Pharmaceutical Co., Ltd. <600521.SS> : Says it receives approval for its olmesartan medoxomil and hydrochlorothiazide tablets from U.S Food and Drug Administration .Says company will be able to sell this medicine in the United States after receiving the FDA approval.  Full Article

Zhejiang Huahai Pharmaceutical announces 2015 dividend payment
Tuesday, 19 Apr 2016 

Zhejiang Huahai Pharmaceutical Co Ltd:To it use undistributed profits to pay a cash dividend of 2 yuan (pre-tax) per 10 shares to shareholders for 2015.To it use additional paid-in capital to distribute three new shares for every 10 shares.  Full Article

BRIEF-Zhejiang Huahai Pharmaceutical to invest in pharma industry park project

* Says it plans to invest in pharma industry park project with total investment at about 10 billion yuan ($1.50 billion)